Iambic
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Multiple Therapeutics
A clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform.
Company HQ City:
San Diego
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
IAM1363, a potential best-in-class, brain-penetrant small molecule inhibitor targeting HER2-driven cancers with high selectivity.
CEO
Thomas Miller, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1 (IAM1363)
When you expect your next catalyst update?
We have several potential catalysts taking place over 2026.
What is your next catalyst (value inflection) update?
We have several potential catalysts across our pipeline, partnerships, and platform advancing in the near-term.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}